drugset
drugset / Trial / NCT01079819

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

NCT01079819 ↗

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects

Timeline

Start
2010-04
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Avagacestat Small molecule 50 mg Oral
Comparator Avagacestat Small molecule 125 mg Oral

Indications

Alzheimer disease